Remdesivir (GS-5734) for COVID-19 Treatment: Past and Recent Updates

(E-pub Ahead of Print)

Author(s): Santhosh Arul, Haripriya Dayalan*

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: SARS-CoV-2 is a pandemic now and several preventive and control measures have been taken by several countries to contain and treat the disease. WHO has been working meticulously and have been providing up to date information and statistics on incidences and death. Several broad spectrum anti-viral drugs are available and have been used in the past to fight against the viral outbreak. Recently Remdesivir, an experimental prodrug from Gilead Sciences have been found potential to be used as a therapy to treat the COVID-19.

Objective: Here we have reviewed the previous findings that are available in the literature and report several findings that are crucial and provide up to date information.

Result: Remdesivir was initially invented for use against Ebola virus treatment and has proved potential against different strains of Ebola, Nipah, and other strains of coronaviruses. Clinical trials with Remdesivir for COVID-19 patients have begun and several off label use of Remdesivir is reported recently. Currently the drug seems to have effect against the SARS-CoV-2 virus with side effects among few patients. The results although are not conclusive are partly promising. This review provides past and recent updates on the use of Remdesivir.

Conclusion: From the review we conclude that the drug Remdesivir is known to exhibit its mechanism of action by terminating the RNA synthesis and it is a potential drug against the novel corona virus.

Keywords: SARS-CoV-2, Coronavirus, Remdesivir, clinical trial, RNA Synthesis, mechanismSARS-CoV-2, Coronavirus, Remdesivir, clinical trial, RNA Synthesis, mechanism

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/2666796701999201216102250

Article Metrics

PDF: 1